A novel strategy for targeting castrate-resistant prostate cancer

  • Risbridger, Gail (Primary Chief Investigator (PCI))
  • Tilley, Wayne D. (Chief Investigator (CI))
  • Furic, Luc (Chief Investigator (CI))
  • Sandhu, Shahneen K. (Chief Investigator (CI))
  • Azad, Arun (Chief Investigator (CI))
  • Selth, Luke A. (Chief Investigator (CI))
  • Lawrence, Mitchell (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Modern drugs for advanced prostate cancer are based on androgen blockade, starving the tumour of hormones. However, the tumour escapes this treatment and metastatic disease arises. In this project we will study the genomic and functional differences between individual prostate cancer metastases as they adapt to contemporary treatments. We aim to identify new strategies to halt the growth of advanced metastatic prostate cancer.
Effective start/end date1/01/1831/12/21


  • National Health and Medical Research Council (NHMRC) (Australia): A$799,440.00